Researchers from Nankai University and collaborating institutions have identified a novel proteolysis targeting chimera (PROTAC) molecule that effectively and selectively degrades multiple ...
Reducing the time and expense of engineering PROTAC degraders remains a significant challenge in the pharmaceutical industry. A PROTAC is composed of an E3 ligase ligand (E3-L), a protein of interest ...
Announcing a new publication for Acta Materia Medica journal. Prostate cancer (PrCa) is the most prevalent urogenital cancer affecting men. PrCa is marked by uncontrolled cellular growth that leads to ...